This article is more than 5 years old. Information may no longer be current.

Lumenis granted worldwide licensing rights to retinal laser therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

YOKNEAM, Israel — Lumenis has acquired exclusive worldwide licensing rights to SRT, a laser therapy designed to treat retinal diseases, the company said in a press release.

SRT is a “novel technology that selectively targets and confines the treatment to specific cells at the back of the retina,” Lumenis said in the release. The company adds the laser generates little heat, leaving the surrounding photoreceptors undamaged and normal function sustained.

Lumenis believes the potential application for the laser will include diabetes and age-related macular degeneration. The company adds it plans to start an expanded international multicenter clinical study later this year.